Diagnostic Criteria for Decompensated Chronic Liver Disease in Children
Decompensated chronic liver disease (DCLD) in children is diagnosed by the presence of clinical complications including ascites, variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis, recurrent cholangitis, or jaundice in a child with established chronic liver disease. 1
Clinical Manifestations Defining Decompensation
The transition from compensated to decompensated disease is marked by specific clinical events:
- Ascites (most common first decompensation event)
- Variceal hemorrhage (hematemesis or melena)
- Hepatic encephalopathy (altered mental status, asterixis)
- Jaundice (progressive hyperbilirubinemia)
- Spontaneous bacterial peritonitis
- Recurrent cholangitis (in cholestatic diseases)
These complications represent the critical threshold where chronic liver disease transitions from a compensated state to one requiring urgent transplant evaluation. 1
Supporting Laboratory Criteria
While clinical events define decompensation, laboratory abnormalities provide supporting evidence:
- Conjugated hyperbilirubinemia (direct bilirubin elevation)
- Severe hypoalbuminemia (albumin <2.5 g/dL)
- Coagulopathy (INR >1.5, uncorrectable with vitamin K)
- Thrombocytopenia (<150 × 10⁹/L, suggesting portal hypertension)
- Anemia (from variceal bleeding or hypersplenism)
Imaging Findings
Ultrasound demonstrates:
- Irregular hepatic surface (nodular contour)
- Splenomegaly (portal hypertension marker)
- Ascites (free fluid in peritoneal cavity)
- Increased portal vein diameter (>12 mm in children)
- Portosystemic collaterals (caput medusae, varices)
Renal Dysfunction Assessment
Acute kidney injury (AKI) in decompensated cirrhosis should be diagnosed using KDIGO criteria adapted for children:
- Stage 1A: SCr increase ≥0.3 mg/dL in <48h OR ≥50% increase in <7 days, with SCr <1.5 mg/dL
- Stage 1B: Same criteria but SCr ≥1.5 mg/dL
- Stage 2: SCr increase 2-2.9× baseline
- Stage 3: SCr increase ≥3× baseline OR SCr ≥4.0 mg/dL
The distinction between Stage 1A and 1B matters because Stage 1B carries worse prognosis. 4
For chronic renal assessment in children with liver disease, do not rely on serum creatinine alone. Use either:
- Revised Schwartz Formula: GFR = 0.413 × [height (cm) / sCr (mg/dL)]
- Cystatin C (preferred in young children; level >1.06 mg/L suggests GFR <80 mL/min/1.73 m²)
Disease-Specific Thresholds for Urgent Evaluation
Certain conditions warrant immediate transplant evaluation even before classic decompensation:
- Biliary atresia post-Kasai: Total bilirubin >6 mg/dL at 3 months post-procedure (only 16% survive to 2 years with native liver)
- Progressive familial intrahepatic cholestasis (PFIC): Intractable pruritus or deforming xanthomas despite preserved synthetic function
- Alagille syndrome: Severe pruritus affecting quality of life
Critical Pitfalls
Do not wait for all classic decompensation criteria to be met. Children with chronic liver disease showing poor weight gain, growth failure, or deteriorating synthetic function should be referred for transplant evaluation even without overt ascites or encephalopathy. 1
Recognize that decompensation can present acutely or insidiously. Some children develop rapid acute decompensation requiring hospitalization, while others have slow progression with mild ascites or grade 1-2 encephalopathy not initially requiring admission. Both pathways represent true decompensation. 5
In resource-limited settings where advanced testing is unavailable, a defensible syndromic diagnosis can be made with a minimum dataset: fractionated bilirubin, albumin, INR, complete blood count, hepatitis serology, and grayscale ultrasound. 2